Skip Navigation


NDT Advance Access originally published online on June 23, 2009
Nephrology Dialysis Transplantation 2009 24(11):3454-3460; doi:10.1093/ndt/gfp309
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/11/3454    most recent
gfp309v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Carrero, J. J.
Right arrow Articles by Frostegård, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carrero, J. J.
Right arrow Articles by Frostegård, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press [on behalf of ERA-EDTA]. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org



Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis

Juan Jesús Carrero1,*, Xiang Hua3,*, Peter Stenvinkel1, Abdul Rashid Qureshi1, Olof Heimbürger1, Peter Bárány1, Bengt Lindholm2 and Johan Frostegård3

1 Divisions of Renal Medicine 2 Baxter Novum, Department of Clinical Science, Intervention and Technology 3 Division of Emergency Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

Correspondence and offprint requests to: Peter Stenvinkel; E-mail: peter.stenvinkel{at}ki.se



  Abstract

Background. Atherosclerosis is an inflammatory disease where oxidized low-density lipoprotein may play an important role through phosphorylcholine (PC)-exposing inflammatory phospholipids. Both atherosclerosis and its clinical consequence cardiovascular disease (CVD) are highly prevalent in patients with end-stage renal disease (ESRD). We here study the association between IgM antibodies against phosphorylcholine-A (anti-PC) and risk of death in patients undergoing haemodialysis (HD).

Methods. We performed a prospective observational study examining the relationship between anti-PC concentrations and mortality risk in a well-characterized cohort of 203 prevalent HD patients [56% men, median age 66 (interquartile range 51–74) years, vintage time 29 (15–58) months] with a mean follow-up period of 29 (14–58) months.

Results. Median anti-PC levels were lower in HD patients with systemic collagen vascular disease (18.9 versus 45.2 U/mL, P = 0.01) and in patients who died during the follow-up period (29.5 versus 53.9 U/mL; P = 0.0008). The patients with an anti-PC value below the median (42.1 U/mL) had a higher mortality rate with a crude hazard ratio (HR) of 2.13 (95% CI 1.40–3.22). These patients remained at higher risk of death (HR 1.76; 95% CI 1.13–2.74) even after adjustment for traditional risk factors (age, sex, smoking habits, CKD aetiology, CVD and diabetes), protein-energy wasting and inflammation (HR 1.70; 95% CI 1.19–2.68).

Conclusion. Low levels of natural IgM antibodies against PC are independent predictors of death among HD patients. Further studies are needed to define the clinical role of such measurements and to explore potentials for active immunization, with PC as an antigen, or passive immunization, aiming at raising levels of protective anti-PC.

Keywords: atherosclerosis; haemodialysis; inflammation; IL-6; phosporylcholine


*Both authors equally contributed.

Received for publication: 20. 1.09
Accepted in revised form: 3. 6.09


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.